跳至主要内容
临床试验/NCT04844632
NCT04844632Unknown不适用

COVID19 Vaccination: Clinical, Laboratory and Cellular Monitoring

University of Roma La Sapienza1 个研究点 分布在 1 个国家目标入组 5,000 人开始时间: 2021年2月11日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
5,000
试验地点
1
主要终点
Adverse Event Following Immunization - AEFI

研究概览

简要总结

Primary objective:

  1. Monitor adverse events (Adverse Event Following Immunization - AEFI) in vaccinated subjects and analyze the associations with: (a) demographic variables and anthropometric parameters (sex, age, BMI, etc.); (b) socioeconomic-cultural variables; (c) co-morbidities.

Secondary objectives:

  1. Monitor the antibody response in vaccinated subjects and analyze the associations with: (a) demographic variables and anthropometric parameters (sex, age, BMI, etc.); (b) socioeconomic-cultural variables; (c) co-morbidities.
  2. Assess the quantity (antibody titer) and quality of the anti-Spike immune response induced by vaccination.
  3. Evaluate the dynamics of the infection and the protective efficacy of the vaccine against infection / disease by studying the incidence and titre of antibodies against Nucleoprotein (N) induced by natural infection;
  4. Evaluate the neutralizing capacity of sera vs. a panel of sera selected and analyzed in house and in in vitro microneutralization systems with live virus;
  5. To evaluate the cell-mediated immune response (CMI) to vaccination against SARS-CoV-2 in a subgroup of vaccinees.

Methodology:

  1. Administration at baseline of a questionnaire for the collection of clinical data.
  2. Perform a blood sample to measure antibody response in vaccinated subjects
  3. Administer a questionnaire to evaluate adverse events after vaccination
  4. Reassess the antibody response 1 month after complete vaccination and 6 and 12 months after the start of vaccination
  5. An antibody assay will be drawn in a subgroup before subjecting the subject to the vaccine.
  6. In a subgroup, the blood collected will also be collected in a heparinized tube for the study of cell-mediated immunity.
  7. In the event that a subject participating in the study presents during the course of the observation the positivity for the molecular research of SARS-CoV-2 RNA to the oro-nasopharyngeal swab, a new sample will be performed and sent to the Istituto Superiore di Sanità for the search for viral variants.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All subjects vaccinated or to be vaccinated at the AOU Policlinico Umberto I and who will agree to join the study.

排除标准

  • All subjects who refuse to give consent or who have contraindications to vaccination.

结局指标

主要结局

Adverse Event Following Immunization - AEFI

时间窗: 12 months from immunization

Adverse events (Adverse Event Following Immunization - AEFI) monitoring in vaccinated subjects and analyze associations with: (a) demographic variables and anthropometric parameters (sex, age, BMI, etc.); (b) socioeconomic-cultural variables; (c) co-morbidities.

次要结局

  • Anti- Nucleoprotein (N) induced by natural infection evaluation(1, 3, 6, 12 months from immunization)
  • Neutralizing capacity of sera(1, 3, 6, 12 months from immunization)
  • Antibody response in vaccinated subject(1, 3, 6, 12 months from immunization)
  • Cell-mediated immune response(Time 0 (before immunization) 3, 10, 21, 30 days; 1, 3, 6 months from immunization)
  • Anti-Spike immune response(1, 3, 6, 12 months from immunization)

研究者

发起方
University of Roma La Sapienza
申办方类型
Other
责任方
Principal Investigator
主要研究者

Stefania Basili

Full Professor

University of Roma La Sapienza

研究点 (1)

Loading locations...

相似试验

COVID19 Vaccination: Clinical, Laboratory and... | 临床试验